Arbele Corp.

ARB203 Clin1 GI cancers; ARB204 Clin0 GI cancers; ARB301 Clin0 GI cancers; ADC001 Clin0 GI cancers; ARB101A Clin1 GI cancer; ARB001 Clin0 colrectal cancer; ARB102A Clin0 GI cancer; ARB011 Clin0 Gi cancers; ARB103A RD GI cancer;

Arbele Corp. is focused on developing innovative immunotherapies for the treatment of gastrointestinal cancers and other solid tumors. Arbele has a suite of therapeutics including their Tri-Ax/Bispecific antibody platform, Antibody Drug Conjugate (ADC), and Advanced Cell Therapy (CAR). Their research centers around the Cadherin-17 (CDH17) biomarker, which they have identified as a highly specific target for these cancers. Arbele's proprietary CDH17 biomarker technology enables them to develop targeted therapies that are more effective and have fewer side effects compared to traditional treatments. Their lead product, ARB202, is a bispecific T-cell engager antibody that binds to both CDH17 and CD3, redirecting T cells to attack cancer cells expressing CDH17. ARB202 is currently in clinical development, with ongoing Phase I studies evaluating its safety, tolerability, and efficacy in patients with advanced gastrointestinal cancers.

Jobs: